Untranslated

86-21-64556180

cpd-service@caerulumpharma.com

Home
About Us
Products
Solutions
FAQs
Contact Us

Home
Products
All products

Products Categories

Antineoplastic
- ACC
- Adenosine A2A
- ALK
- Androgen receptor inhibitor
- Apoptosis stimulant
- ATR
- AXL
- BCl2-BH4
- Bcr-Abl
- BRAF
- BTK
- CDK
- Chk1
- CYP17
- DNA alkylating agent
- EED
- EGFR
- EP4
- ER
- FAK
- FGFR
- FLT3
- Glutaminase
- IDO
- IRA
- KIT
- LXR
- MDM2
- MEK
- MET
- Nrf2
- P90RSK
- P97
- PAKS
- PARP
- PI3K
- Plk-1
- SMYD2
- SRC
- TOPK
- VEGFR
Hypoglycemic drugs
- DPP-4
- SGLT-1
- SGLT-2
Others
- 5HT
- AMPK
- Arginase
- CRF-1
- CXCR2
- FLAP
- FXR
- GABA
- Gi activator
- GR
- JAK
- LABA
- mAChRs
- NF-κB
- NRTI
- PPAR
- RIP1
- S1PR
- SGC
- SYK
- α2δ-1
- αIIbβ3
- β2-adrenoceptor
- σ1

All products

GDC-0927
CPD101782
CPD101759
IPN-60090
CPD101733
CPD101734
CPD101735
CPD101736
LX-2761
CPD101738
CPD101680
TNO155
BAY-1251152
ASN-002
RBN-2397
UNC6852
CPD101389
SNDX-5613
CPD101263
CPD101264
CPD101265
CPD101266
CPD101238
VTP50469
Fezolinetant
SEP-363856
PRI-724
CPD1584-B3
CPD1584-B3 HCl
Olinciguat

<< < Previous 16 17 18 19 20 21 22 Next > >> Page 19 / 33

Contact Us

3rd Floor, Building 4, 3918 Daye Road, Fengxian District, Shanghai
86-21-64556180
Within China:
sales-cpd@caerulumpharma.com
International:
cpd-service@caerulumpharma.com

Inquiry

For inquiries about our products, please leave your email with us and we will be in touch within 24 hours.Inquiry

Latest News

AstraZeneca receives regulatory boost for oncology drugs

AstraZeneca receives regulatory boost for...

AstraZeneca received a double boost for its oncology portfolio on Tuesday, after US and European regulators accepted regulatory submissions for its drugs, the first step towards winning approval for these medicines. ...

Top 7 Trends In Pharmaceutical Research In 2018

Top 7 Trends In Pharmaceutical Research I...

Being under ever-increasing pressure to compete in a challenging economic and technological environment, pharmaceutical and biotech companies must continually innovate in their R&D programmes to stay ahead ...

ARS-1620: A promising new inhibitor for KRAS-mutant cancers

ARS-1620: A promising new inhibitor for K...

According to a study published in Cell, researchers have developed a specific inhibitor for KRASG12C called ARS-1602 that induced tumor regression in mice. “This study provides in vivo evidence that mutant KRAS can be...

AstraZeneca receives regulatory boost for oncology drugs

AstraZeneca receives regulatory boost for...

AstraZeneca received a double boost for its oncology portfolio on Tuesday, after US and European regulators accepted regulatory submissions for its drugs, the first step towards winning approval for these medicines. ...

Top 7 Trends In Pharmaceutical Research In 2018

Top 7 Trends In Pharmaceutical Research I...

Being under ever-increasing pressure to compete in a challenging economic and technological environment, pharmaceutical and biotech companies must continually innovate in their R&D programmes to stay ahead ...

prev

next

© Copyright - 2010-2022 : All Rights Reserved.

FAQs
Downloadable
Contact Us

QR Code

WhatsApp Online Chat !

TOP

Previous Maximize